We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.


0.00 (0.0%)
Dec 01 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 160,257
Bid Price 1.28
Ask Price 1.42
News -
Day High 1.39


52 Week Range


Day Low 1.32
Company Name Stock Ticker Symbol Market Type
InflaRx NV IFRX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 1.35 20:00:00
Open Price Low Price High Price Close Price Prev Close
1.38 1.32 1.39 1.35 1.35
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
611 160,257 $ 1.36 $ 217,815 - 1.14 - 6.15
Last Trade Time Type Quantity Stock Price Currency
16:00:49 33 $ 1.32 USD

InflaRx NV Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
72.51M 54.12M - 20.16M -29.48M -0.54 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

InflaRx NV News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No IFRX Message Board. Create One! See More Posts on IFRX Message Board See More Message Board Posts

Historical IFRX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.431.601.211.34190,621-0.08-5.59%
1 Month1.551.601.141.39653,997-0.20-12.9%
3 Months3.924.151.141.71342,110-2.57-65.56%
6 Months4.174.701.142.69271,251-2.82-67.63%
1 Year2.616.151.143.74406,546-1.26-48.28%
3 Years4.246.880.77623.67562,043-2.89-68.16%
5 Years29.1453.100.77624.86628,169-27.79-95.37%

InflaRx NV Description

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |